# Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

> **NCT00509899** · PHASE1,PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 154 (actual)

## Conditions studied

- Myelofibrosis
- Polycythemia Vera
- Thrombocytosis

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT00509899
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2007-12
- **Final completion:** 2017-02
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2018-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00509899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00509899, "Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00509899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*